 | • レポートコード：B-MOR-08429 • 出版社/出版日：Mordor Intelligence / 2018年5月22日 • レポート形態：英文、PDF、107ページ • 納品方法：Eメール（受注後2営業日） • 産業分類：医療・製薬 |
| Single User（1名様用） | ￥629,000 (USD4,250) | ▷ お問い合わせ |
| Team User（7名様用） | ￥666,000 (USD4,500) | ▷ お問い合わせ |
| Corporate User | ￥1,295,000 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本資料は、過活動膀胱治療の世界市場について調べ、過活動膀胱治療の世界規模、市場動向、市場環境、治療法別（抗コリン薬、ミラベグロン、神経刺激、膀胱内注入）分析、疾患別（特発性過活動膀胱、神経性過活動膀胱）分析、アメリカ市場規模、ヨーロッパ市場規模、アジア市場規模、企業の競争環境、関連企業情報などをまとめた調査レポートです。 ・イントロダクション ・エグゼクティブサマリー ・過活動膀胱治療の世界市場インサイト ・過活動膀胱治療の世界市場環境 ・過活動膀胱治療の世界市場動向 ・過活動膀胱治療の世界市場規模 ・過活動膀胱治療の世界市場規模：治療法別（抗コリン薬、ミラベグロン、神経刺激、膀胱内注入） ・過活動膀胱治療の世界市場規模：疾患別（特発性過活動膀胱、神経性過活動膀胱） ・過活動膀胱治療の世界市場：地域別市場規模・分析 ・過活動膀胱治療の北米市場規模・予測 ・過活動膀胱治療のアメリカ市場規模・予測 ・過活動膀胱治療のヨーロッパ市場規模・予測 ・過活動膀胱治療のアジア市場規模・予測 ・過活動膀胱治療のインド市場規模・予測 ・過活動膀胱治療の韓国市場規模・予測 ・関連企業情報・競争状況 |
The global overactive bladder treatment market is expected to register a CAGR of about 2.9% over the forecast period, 2018-2023. The overactive bladder treatments includes various therapies like, anticholinergics, mirabegron, etc., that are used to treat the sudden, involuntary contraction of the muscle in the urinary bladder wall leading to urinary urgency, frequency, nocturia, and urge-incontinence.
Aging Population and Rising Incidence of Diseases Characterized By OAB
In 2017, there were approximately 950 million people who were 60 years old or above, comprising 13% of the global population, and is growing by about 3% every year. Incontinence generally increases with aging. As per a global population-based survey, the estimated prevalence of overactive bladder (OAB) in Europe and Canada was found to be 12.8% in women and 10.8% in men. OAB has a major negative impact on quality of life and health of the aged population. With the increasing burden of OAB, along with other urinary diseases, the growth of the overactive bladder treatment market is likely to be high. Other factors, such as the development of innovative intravesical therapies and aggressive marketing by pharmaceuticals companies, are also expected to expand the market.
Undesired Systemic Effects of the Current OAB Treatments
Anticholinergic have been linked to the burden to dementia or Alzheimer’s disease in a few recent studies. In a recent publication by SL Gray, 3434 participants were studied and a 10-year cumulative dose response relationship was found to exist between the usage of anticholinergic drugs and the risk of developing dementia. Anticholinergic has also been linked with increased mortality and cardiovascular diseases. These factors may deter healthcare providers from using these treatment options. Also the increasing awareness about these side effects among users will lead to the slowdown of the growth of this market.
North America to Dominate the Market
North America has dominated the overactive bladder treatment market, which can be primarily attributed to its well-established healthcare industry which has favorable reimbursement of overactive bladder treatment, growing prevalence of the disease with rising age, and the presence of major players. Asia-Pacific region is expected to witness the highest CAGR during the forecast period, due to rising prevalence of bladder overactivity, increasing geriatric population, rising healthcare expenditure, and growing awareness of overactive bladder.
Major Players: ALLERGAN PLC., APOTEX INC., ASTELLAS PHARMA INC., AUROBINDO PHARMA LIMITED, COGENTIX MEDICAL INC., ENDO INTERNATIONAL PLC, HISAMITSU PHARMACEUTICAL CO. INC., INTAS PHARMACEUTICALS LTD, JOHNSON & JOHNSON, MACLEODS PHARMACEUTICALS LTD, MEDTRONIC PLC, MYLAN NV, PFIZER INC., SANOFI, AND TEVA PHARMACEUTICAL INDUSTRIES LIMITED, amongst others.
Reasons to Purchase the Report
• Current and future overactive bladder treatment market outlook in the developed and emerging markets
• Analysis of various perspectives of the market with the help of Porter’s five forces analysis
• The segment that is expected to dominate the market
• Regions that are expected to witness the fastest growth during the forecast period
• Identify the latest developments, market shares, and strategies employed by the major market players
• 3 months analyst support, along with the Market Estimate sheet (in Excel)
Customization of the Report
This report can be customized to meet your requirements. Please connect with our representative, who will ensure you to get a report that suits your needs.
レポート目次1. Introduction
1.1 Market Definition
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview
5.1 Current Market Scenario
5.2 Porter’s Five Forces Analysis
5.2.1 Bargaining Power of Suppliers
5.2.2 Bargaining Power of Consumers
5.2.3 Threat of New Entrants
5.2.4 Threat of Substitute Product and Services
5.2.5 Competitive Rivalry Within the Industry
6. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
6.1 Market Drivers
6.1.1 Developing Innovative Intravesical Therapies
6.1.2 Aggressive Marketing by Pharma Companies
6.1.3 Aging Population and Rising Incidence of Diseases Characterized By OAB
6.2 Market Restraints
6.2.1 Undesired Systemic Effects of Current OAB Treatments
6.3 Opportunities
6.4 Key Challenges
7. Market Segmentation
7.1 By Therapy
7.1.1 Anticholinergics
7.1.1.1 Solifenacin
7.1.1.2 Oxybutynin
7.1.1.3 Fesoterodine
7.1.1.4 Darifenacin
7.1.1.5 Tolterodine
7.1.1.6 Other Anticholinergics
7.1.2 Mirabegron
7.1.3 Neurostimulation
7.1.4 Intravesical Instillation
7.2 By Disease
7.2.1 Idiopathic Overactive Bladder
7.2.2 Neurogenic Overactive Bladder
7.2.2.1 Overactive Bladder in Parkinson’s Disease
7.2.2.2 Overactive Bladder in Stroke
7.2.2.3 Overactive Bladder in Multiple Sclerosis
7.2.2.4 Overactive Bladder in Spinal Cord Injury
7.2.2.5 Overactive Bladder in Other Disorders
7.3 By Geography
7.3.1 North America
7.3.1.1 United States
7.3.1.2 Canada
7.3.1.3 Mexico
7.3.2 Europe
7.3.2.1 France
7.3.2.2 Germany
7.3.2.3 United kingdom
7.3.2.4 Italy
7.3.2.5 Spain
7.3.2.6 Rest of Europe
7.3.3 Asia-Pacific
7.3.3.1 India
7.3.3.2 Australia & New Zealand
7.3.3.3 South korea
7.3.3.4 Rest of Asia-Pacific
7.3.4 Rest of World
7.3.4.1 Saudi Arabia
7.3.4.2 Brazil
7.3.4.3 Others
8. Competitive Landscape
8.1 Mergers & Acquisition Analysis
8.2 Agreements, Collaborations, and Partnerships
8.3 New Products Launches
9. Key Players
9.1 Allergan PLC
9.2 Apotex Inc.
9.3 Astellas Pharma Inc.
9.4 Aurobindo Pharma Limited
9.5 Cogentix Medical Inc
9.6 Endo International PLC
9.7 Hisamitsu Pharmaceutical Co. Inc
9.8 Intas Pharmaceuticals Ltd
9.9 Johnson & Johnson
9.10 Macleods Pharmaceuticals Ltd
9.11 Medtronic PLC
9.12 Mylan NV
9.13 Pfizer Inc
9.14 Sanofi
9.15 Teva Pharmaceutical Industries Limited
*List Not Exhaustive
10. Future of the Market